AS
Astrana Health, Inc.
ASTH · NASDAQ
$38.06 +0.82% (+$0.31)
1M +10.38%
Market Cap $1.89B
P/E Ratio 46.54x
Div. Yield -
ROE 5.09%
Bulios Fair Price
$56.95
49.6% upside
Current Price
$38.06
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ASTH is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
62 /100
Fair EV/EBITDA 14.10x
P/S 0.49x
P/B 2.27x
Growth
68 /100
Growing Rev. growth 40.62%
FCF growth 20.86%
Book val. growth 12.83%
Profitability
16 /100
Weak Net margin 1.05%
Op. margin 2.61%
FCF margin 4.12%
Quality
32 /100
Poor ROE 5.09%
ROA 1.78%
Asset turnover 1.68x
Debt
39 /100
Moderate Current ratio 1.23x
Int. coverage 1.89x
Net debt/EBITDA 3.31x
Stability
71 /100
Stable Rev. volatility 18.18%
EPS volatility 41.40%
Profitable years 5
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ASTH
Online
Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Brandon K. Sim
Employees
3,000
Headquarters
Alhambra
Upcoming events
05 NOV
Earnings
Upcoming earnings report